Oncodesign Services Receives Second Consecutive Global Excellence Award
We are proud to announce that Oncodesign Services has been named “Oncology CRO of the Year 2025 – France” by Global Health & Pharma, marking the second consecutive year we have received this prestigious recognition. This achievement reflects our position as a leading contract research organization (CRO) specializing in drug discovery and preclinical development, with a particular focus on oncology.
Recognition as Oncology CRO of the Year in 2024 and 2025 follows our 2023 recognition as “Best Preclinical Services and Drug Discovery Company – France”, highlighting our continued commitment to scientific excellence, cutting-edge innovation, and client-focused service across the drug development value chain.
“This recognition is a testament to the passion, precision, and partnership that define how we work at Oncodesign Services,” said Cedric Lamy, Chief Business Officer at Oncodesign Services. “From our advanced pharmacology platforms to our imaging capabilities, we are pushing the boundaries of what is possible in oncology research and beyond.”
As we continue to drive innovation in oncology, we look forward to connecting with our peers, clients, and collaborators at the AACR Annual Meeting 2025 in April. Stop by our booth #2849 to learn more about how we are shaping the future of preclinical drug development, or secure a meeting with our team in advance via our booking portal. More information here
A heartfelt thank you to our clients, collaborators, and incredible team for making this achievement possible!